ScreenerHero

RCKTRocket Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · rocketpharma.com
3.510USD+0.86%Mkt Cap: 385.31M $P/E: —

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap385.31M $
Enterprise Value123.07M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-223.12M $
Revenue/Share—
Last Price3.510 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees202
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS77313F1066
Valuation
P/E (Trailing)—
P/E (Forward)-2.67
PEG—
EV/EBITDA-0.68
EV/Revenue—
P/S—
P/B1.03
EPS (TTM)-0.16
EPS (Forward)-1.30
52W Range
2.53034% of range5.450
52W High5.450 USD
52W Low2.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-80.49%
ROA-67.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-190.01M $
CapEx (TTM)440.00K $
FCF Margin—
FCF Yield22.36%
Net Debt-258.95M $
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.09
Current Ratio9.24
Quick Ratio9.06
Book Value/Sh3.367 USD
Cash/Share2.585 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 5, 2018
Splits
Last Split1:4
Split DateJan 5, 2018
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.841 USD
Upside (mean)+151.9%
Target Range3.000 USD – 15.00 USD
$3.000+151.9% to mean$15.00
# Analysts11
Ownership
Shares Out.109.77M
Float87.54M
Insiders3.25%
Institutions91.58%
Short Interest
Short Ratio8.4d
Short % Float17.30%
Short % Out.14.12%
Shares Short15.50M
Short (prev mo.)18.16M
Technical
SMA 503.410 (+2.9%)
SMA 2003.550 (-1.1%)
Beta0.47
S&P 52W Chg18.16%
Avg Vol (30d)1.46M
Avg Vol (10d)1.28M
Technical Indicators
RSI (14)52.6
MACD0.0309
MACD Signal0.0219
MACD Hist.+0.0090
BB Upper3.739 USD
BB Middle3.397 USD
BB Lower3.055 USD
BB Width20.11%
ATR (14)0.1924 USD
Vol Ratio (20d)0.62x